公开(公告)号：US20180022825A1

公开(公告)日：2018-01-25

申请号：US15604556

申请日：2017-05-24

Applicant: Novartis AG

Inventor： Stefan EWERT ,  Yasser KHDER ,  Alexander KOCH

IPC: C07K16/42 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/4241 ,  A61K39/39566 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/4208 ,  C07K2317/21 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.

公开(公告)号：US20240067750A1

公开(公告)日：2024-02-29

申请号：US18157312

申请日：2023-01-20

Applicant: NOVARTIS AG

Inventor： Jorg EDER ,  Stefan EWERT ,  Ulrich HASSIEPEN ,  Yasser KHDER ,  Lorenz MAYR ,  Samu MELKKO ,  Nikolaus SCHIERING

IPC: C07K16/36 ,  A61K39/395 ,  A61K45/06 ,  A61P7/02 ,  C07K16/40

CPC classification number: C07K16/36 ,  A61K39/3955 ,  A61K45/06 ,  A61P7/02 ,  C07K16/40 ,  A61K2039/505

Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20210221871A1

公开(公告)日：2021-07-22

申请号：US17059934

申请日：2019-05-30

Applicant: Novartis AG

Inventor： Stefan EWERT ,  Meghan Marie HOLDORF ,  Elisabetta TRAGGIAI

IPC: C07K16/08 ,  A61K39/00

Abstract: The present invention relates to anti-HBsAg antibodies, antibody fragments, and their uses for the prevention and treatment of hepatitis B virus infection and associated diseases.

公开(公告)号：US20200308301A1

公开(公告)日：2020-10-01

申请号：US16765274

申请日：2018-11-20

Applicant: NOVARTIS AG

Inventor： Stefan EWERT ,  Alexander Wolfgang KOCH

IPC: C07K16/36 ,  C07K16/00 ,  A61P7/04

Abstract: The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.

公开(公告)号：US20220025070A1

公开(公告)日：2022-01-27

申请号：US17309713

申请日：2019-12-17

Applicant: NOVARTIS AG

Inventor： Stefan EWERT ,  Andrew GREEN ,  Alexander Wolfgang KOCH

IPC: C07K16/42

Abstract: The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies (e.g., NOV1401), and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies (e.g., NOV1401), as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies (e.g., NOV1401), and to related methods for managing bleeding or bleeding risks.

公开(公告)号：US20170198040A1

公开(公告)日：2017-07-13

申请号：US15382251

申请日：2016-12-16

Applicant: Novartis AG

Inventor： Nicole BALKE ,  Thomas CALZASCIA ,  Stefan EWERT ,  Alan HARRIS ,  Heather Adkins HUET ,  Isabelle ISNARDI ,  Haihui LU ,  Matthew John MEYER ,  Nicholas WILSON ,  Fangmin WU

IPC: C07K16/28 ,  A61K45/06

CPC classification number: C07K16/2803 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/541 ,  A61K2039/545 ,  C07K16/28 ,  C07K16/283 ,  C07K16/2887 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which selectively bind human CD32b. Also provided herein are compositions comprising the antibodies or antigen-binding fragments thereof, methods of using the antibodies or antigen-binding fragments thereof, and methods of making the antibodies or antigen-binding fragments thereof.